secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001104659-24-113480
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva shareholders approve 8.9x stock plan share increase and 25x authorized share increase.
--------------------------------------------------------------------------------

- Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share reserve from 280,000 to 2,500,000 shares.
- Non-employee director annual grant limit raised from 40,000 to 250,000 shares under the amended plan.
- Certificate of Change filed to increase authorized common shares from 14,000,000 to 350,000,000, effective November 1, 2024.
- All four director nominees elected; BDO USA, P.C. ratified as independent auditor for FY2024.
- Shareholders also approved the adjournment proposal, but it was not needed as quorum was present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924113480/0001104659-24-113480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924113480/tm2427299d1d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-113480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer